FDA approves Teva's Ajovy auto-injector device

Migraine patients soon will have the flexibility of quarterly or monthly dosing options of Ajovy (fremanezumab-vfm) injection, now that the Food and Drug Administration has approved Teva’s autoinjector device.

"The approval of the Ajovy autoinjector is another important step forward for Teva and the migraine community," said Brendan O’Grady, Teva executive vice president, North America commercial.

"Ajovy is the only FDA approved anti-CGRP that offers the flexibility of quarterly 675 mg, or monthly 225 mg dosing options, and we are pleased that patients and their healthcare providers will be able to decide if an autoinjector is the right administration option for their needs," O'Grady added.

The Ajovy autoinjector is expected to be available to patients in the coming months.